# Amakem NV

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/amakem

- Industry: Biotechnology
- Headquarters: Belgium
- Website: www.amakem.com
- Total disclosed funding: $7.1M
- Latest round: Series A (Sep 6, 2011)
- Investors on record: 6

## About

Amakem NV is a Belgium-based company focused on the development of innovative solutions in the biopharmaceutical sector, particularly in the field of drug delivery systems.Founded in 2010 in Belgium, Amakem NV specializes in the development of innovative drug delivery systems. The company has undergone strategic shifts to enhance its focus on biopharmaceutical solutions. It has raised a total of EUR 18.00 mn through multiple rounds of funding, with the most recent funding being a Grant of EUR 1.4mn from the Institute for the Promotion of Innovation by Science and Technology in Flanders on January 3, 2013. The founder's history is not publicly documented.Amakem NV offers a unique domain name service through its website Amakem.com, which allows individuals and businesses to purchase domain names for EUR 3,695 or through a structured payment plan of EUR 153.96 per month for 24 months at 0% interest. The company ensures quick accessibility of domain ownership transfer, typically within one to two hours after purchase, catering to a diverse client base including entrepreneurs, startups, and established businesses globally in regions such as North America, Europe, and Asia.Revenue for Amakem NV is generated primarily through domain name sales, structured around direct-to-consumer transactions. Clients can opt for a one-time purchase or a financing plan. The process is designed to be user-friendly, allowing secure transactions with options for payment methods like PayPal or Escrow.com, with the company's EBITDA for the most recent year (2024) reported at EUR 313,327.20.Amakem NV aims to expand its offerings by developing new products in the biopharmaceutical sector, although specific release dates are not available. The company is also exploring opportunities for market expansion into new regions, focusing on increasing its presence in North America and Asia by the end of 2024. The recent Grant funding of EUR 1.4 mn will be utilized to support these initiatives, enhancing Amakem NV's capabilities in drug delivery solutions.

## Funding rounds

- Series A, Sep 6, 2011, $6.1M — Omnes Capital, Forbion, LRM, Vesalius Biocapital, PMV, Life Sciences Research Partners
- Seed, Feb 11, 2010, $1M — LRM, PMV, Life Sciences Research Partners

## Investors

- LRM (https://capitalatlas.ai/funds/lrm) — Seed, Series A
- PMV (https://capitalatlas.ai/funds/pmv) — Seed, Series A
- Life Sciences Research Partners — Seed, Series A
- Omnes Capital (https://capitalatlas.ai/funds/omnes-capital) — Series A
- Forbion (https://capitalatlas.ai/funds/forbion) — Series A
- Vesalius Biocapital (https://capitalatlas.ai/funds/vesalius-biocapital) — Series A